NAVIDEA BIOPHARMACEUTICALS I (NAVB) Stock Analyst Earnings Estimates
NYSEARCA:NAVB - NYSE Arca - US63937X2027 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 915.01K 39.10% | 531.51K -41.91% | 65.65K -87.65% | |
| EBITDA YoY % growth | -10.641M 1.64% | -11.983M -12.62% | -13.955M -16.45% | |
| EBIT YoY % growth | -10.711M 2.29% | -12.06M -12.60% | -14.051M -16.50% | |
| Operating Margin | -1,170.61% | -2,269.09% | -21,402.74% | |
| EPS YoY % growth | -0.48 40.00% | -0.40 16.67% | N/A |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | -0.11 8.33% | % | ||
| Q3 2022 Q2Q % growth | -0.25 -212.50% | % | ||
| Q2 2022 Q2Q % growth | -0.10 -11.11% | % | ||
| Q1 2022 Q2Q % growth | -0.10 9.09% | % | ||
| Q4 2021 Q2Q % growth | -0.12 -9.09% | % | ||
| Q3 2021 Q2Q % growth | -0.08 38.46% | -0.11 | 0.03 | 28.70% |
| Q2 2021 Q2Q % growth | -0.09 18.18% | -0.08 | -0.01 | -10.29% |
| Q1 2021 Q2Q % growth | -0.11 15.38% | -0.08 | -0.03 | -34.80% |
| Q4 2020 Q2Q % growth | -0.11 26.67% | -0.12 | 0.01 | 10.13% |
| Q3 2020 Q2Q % growth | -0.13 23.53% | -0.09 | -0.04 | -41.61% |
| Q2 2020 Q2Q % growth | -0.11 54.17% | -0.12 | 0.01 | 10.13% |
| Q1 2020 Q2Q % growth | -0.13 45.83% | % | ||
| Q4 2019 Q2Q % growth | -0.15 | -0.12 | -0.03 | -22.55% |
| Q3 2019 Q2Q % growth | -0.17 | -0.17 | 0.00 | 1.96% |
| Q2 2019 Q2Q % growth | -0.24 | -0.15 | -0.09 | -56.86% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | 610 -98.79% | % | ||
| Q3 2022 Q2Q % growth | 7.52K -92.20% | % | ||
| Q2 2022 Q2Q % growth | 57.53K -77.96% | % | ||
| Q1 2022 Q2Q % growth | -100.00% | % | ||
| Q4 2021 Q2Q % growth | 50.35K -77.04% | % | ||
| Q3 2021 Q2Q % growth | 96.38K -64.09% | 96.38K | % | |
| Q2 2021 Q2Q % growth | 261.05K -3.71% | 612K | -350.95K | -57.34% |
| Q1 2021 Q2Q % growth | 123.74K -20.82% | 612K | -488.26K | -79.78% |
| Q4 2020 Q2Q % growth | 219.25K 83.78% | 612K | -392.75K | -64.17% |
| Q3 2020 Q2Q % growth | 268.39K 13.34% | 153K | 115.39K | 75.42% |
| Q2 2020 Q2Q % growth | 271.1K 4.23% | 306K | -34.9K | -11.41% |
| Q1 2020 Q2Q % growth | 156.27K 275.47% | % | ||
| Q4 2019 Q2Q % growth | 119.3K | 153K | -33.7K | -22.03% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |